Beta glucans are naturally occurring polysaccharides found in the cell walls of cereals, bacteria, and fungi. Their use in eczema (atopic dermatitis) is primarily supported by scientific interest in their immunomodulatory and skin barrier-enhancing properties. Several small clinical studies and preclinical investigations have explored topical beta glucans for eczema and other inflammatory skin conditions. Some research suggests that topical beta glucan may help reduce inflammation, enhance wound healing, and improve skin hydration, which are relevant to eczema management. For example, a 2013 randomized controlled trial (J Drugs Dermatol. 2013) reported improvements in skin barrier function and symptoms in subjects with atopic dermatitis using a beta glucan-containing cream compared to placebo. Other in vitro and animal studies support the idea that beta glucans can modulate immune responses and promote skin repair.

However, the evidence base remains limited. Most studies are small, of short duration, and often funded by product manufacturers. There is a lack of high-quality, large-scale clinical trials definitively establishing efficacy. While there is a plausible scientific rationale and some early evidence, beta glucan is not a first-line or widely endorsed therapy for eczema in major dermatology guidelines. Its use is considered adjunctive, and more robust, independent research is needed to confirm benefits.